Overview

Nilotinib in Parkinson's Disease

Status:
Completed
Trial end date:
2019-09-28
Target enrollment:
Participant gender:
Summary
This study will assess the safety and tolerability of daily oral administration of nilotinib (150-300mg once daily) in Parkinson's Disease.
Phase:
Phase 2
Details
Lead Sponsor:
Northwestern University
Collaborators:
Michael J. Fox Foundation for Parkinson's Research
University of Iowa
University of Rochester